Revenue Growth QoQ: tharimmune.com (THAR)

Tharimmune (THAR) - corporate logo

The asset structure of Tharimmune, Inc. (THAR) exhibits a pronounced imbalance due to its concentration on anti-itch and anti-cancer antibodies. Quarterly revenue growth reflects the current trend, where the 0.00 level records fresh values. Income is based on grants and drug development partnerships, although global logistics and patent disputes in Asia create serious risks for clinical trials.

THAR (Tharimmune Corp) Quarterly Sales Growth Rate history from 02/21/2024 to 02/18/2026

THAR (Tharimmune Corp): analytical breakdowns and indicator data

- company stock exchange capitalization indicators:
- cash and cash flow indicators:
Analysis of all company metrics:THAR - Tharimmune
Mass-produced product of Tharimmune Inc

Identifying fundamentally resilient assets requires an analysis of cash flow dynamics, where calculating quarterly revenue growth reveals hidden liquidity erosion and the quality of corporate earnings. For Tharimmune, Inc. (THAR), quarter-over-quarter sales growth confirms the commercial efficiency of its diversified immunotherapy pipeline, allowing investors to assess the extent to which the development of cancer and skin disease treatments converts into real financial growth.

Direct competitors

BeiGene Oncology - Quarterly Revenue Growth|HALO: Revenue Growth QoQ|Revolution Medicines Corp (RVMD) - Revenue Growth QoQ|Quarterly Revenue Growth Rate Ascentage Pharma Group International (AAPG)|Revenue Growth QoQ CG Oncology, Inc.|Quarterly Revenue Growth Rate UroGen Pharma Corp URGN|Quarterly Revenue Growth BCAX|Personalis, Inc. - Sales Growth QoQ|Erasca - Quarterly Sales Growth|Quarterly Revenue Increase DCTH|YMAB: Quarterly Sales Growth|Quarterly Revenue Growth Rate Aura Corp|CADL: Quarterly Revenue Growth|ARAY - Quarterly Sales Growth Rate|SLS (SELLAS Life Sciences Group, Inc.) - Quarterly Revenue Growth|ACTU: Quarterly Revenue Increase|Revenue Growth QoQ citiusonc.com (CTOR)|Quarterly Sales Growth Rate TuHURA Biosciences|Revenue Growth QoQ Protara Therapeutics TARA|Fate Therapeutics (FATE) - Quarterly Revenue Growth Rate|WHWK - Revenue Growth QoQ|Quarterly Revenue Growth Rate TScan Therapeutics Inc|championsoncology.com (CSBR) - Revenue Growth QoQ|Sales Growth QoQ XBIT|Quarterly Sales Growth CVM|Sales Growth QoQ OSTX (OS Therapies Incorporated)|Quarterly Revenue Growth RADX|ARTV: Revenue Dynamics QoQ|Quarterly Revenue Growth ANL (Adlai Nortye Ltd)|VERU - Quarterly Sales Growth|tempesttx.com - Quarterly Revenue Growth|Quarterly Revenue Increase XLO (xiliotx.com)|RENB: Quarterly Revenue Growth|Quarterly Sales Growth Mural Oncology plc|Revenue Growth QoQ Kairos Pharma Inc|OKUR: Quarterly Revenue Increase|Quarterly Revenue Growth GDTC|CRIS (Curis) - Quarterly Revenue Increase|Revenue Growth QoQ apollomicsinc.com APLM|Advanced Biomed Corp - Revenue Growth QoQ|GNPX: Quarterly Sales Growth|Calidi Biotherapeutics, Inc. (CLDI) - Quarterly Sales Growth|SBFM: Quarterly Revenue Growth|Quarterly Sales Growth Xenetic Biosciences Inc.|Revenue Growth QoQ Salarius Pharmaceuticals Inc|PPBT: Quarterly Revenue Increase|Quarterly Revenue Growth AONC|BGNE (BeOne Medicines) - Quarterly Revenue Increase|Checkpoint Therapeutics, Inc - Quarterly Sales Growth|elevationoncology.com (ELEV) - Quarterly Revenue Growth Rate|iCAD Inc. - Quarterly Revenue Growth|Quarterly Revenue Growth Rate Ikena Oncology|NTBL: Quarterly Revenue Growth|Quarterly Revenue Growth Rate Viracta (VIRX)|MOR (MorphoSys AG) - Quarterly Revenue Growth|NAYA: Quarterly Revenue Increase|Revenue Growth QoQ Ascentage Pharma Group Ltd (AAPGV)